Reginster JY - Search Results

1

Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial.

Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Reginster JY, et al. Osteoporos Int. 2002 Dec;13(12):925-31. doi: 10.1007/s001980200129. Osteoporos Int. 2002. PMID: 12459934 Clinical Trial.

2

Strontium ranelate: a new paradigm in the treatment of osteoporosis.

Reginster JY, Lecart MP, Deroisy R, Lousberg C. Reginster JY, et al. Expert Opin Investig Drugs. 2004 Jul;13(7):857-64. doi: 10.1517/13543784.13.7.857. Expert Opin Investig Drugs. 2004. PMID: 15212623 Review.

3

Prevention of postmenopausal bone loss by rectal calcitonin.

Reginster JY, Jupsin I, Deroisy R, Biquet I, Franchimont N, Franchimont P. Reginster JY, et al. Calcif Tissue Int. 1995 Jun;56(6):539-42. doi: 10.1007/BF00298586. Calcif Tissue Int. 1995. PMID: 7648483 Clinical Trial.

4

A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.

Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P. Reginster JY, et al. Am J Med. 1995 May;98(5):452-8. doi: 10.1016/S0002-9343(99)80344-1. Am J Med. 1995. PMID: 7733123 Clinical Trial.

5

A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium.

Reginster JY, Meurmans L, Deroisy R, Jupsin I, Biquet I, Albert A, Franchimont P. Reginster JY, et al. Eur J Clin Invest. 1994 Aug;24(8):565-9. doi: 10.1111/j.1365-2362.1994.tb01108.x. Eur J Clin Invest. 1994. PMID: 7982445 Clinical Trial.

6

Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.

Reginster JY, Gaspar S, Deroisy R, Zegels B, Franchimont P. Reginster JY, et al. Osteoporos Int. 1993 Sep;3(5):261-4. doi: 10.1007/BF01623830. Osteoporos Int. 1993. PMID: 8400608 Clinical Trial.

7

High prevalence of low femoral bone mineral density in elderly women living in nursing homes or community-dwelling: a plausible role of increased parathyroid hormone secretion.

Reginster JY, Deroisy R, Pirenne H, Frederick I, Dewe W, Albert A, Collette J, Zheng SX, Gosset C. Reginster JY, et al. Osteoporos Int. 1999;9(2):121-8. doi: 10.1007/s001980050124. Osteoporos Int. 1999. PMID: 10367038

8

Intermittent cyclic tiludronate in the treatment of osteoporosis.

Reginster JY, Christiansen C, Roux C, Fechtenbaum J, Rouillon A, Tou KP. Reginster JY, et al. Osteoporos Int. 2001;12(3):169-77. doi: 10.1007/s001980170126. Osteoporos Int. 2001. PMID: 11315234 Clinical Trial.

9

Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.

Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T. Reginster JY, et al. Osteoporos Int. 2003 Sep;14(9):741-9. doi: 10.1007/s00198-003-1432-1. Epub 2003 Jun 19. Osteoporos Int. 2003. PMID: 12827224 Clinical Trial.

10

Strontium ranelate (Fujisawa/Servier).

Jupsin I, Collette J, Henrotin Y, Bruyere O, Sarlet N, Reginster JY. Jupsin I, et al. Among authors: reginster jy. Curr Opin Investig Drugs. 2005 Apr;6(4):435-44. Curr Opin Investig Drugs. 2005. PMID: 15898351

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

989 results

Search Page

Filters